Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease

Alzheimer Disease Clinical Trial

Official title:

Individual Patient Expanded Access Investigation New Drug (IND) Application for Administration of Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT04855955
• Other study ID #: CTXSP0001
• Status: No longer available

Study information

• Verified date: February 2024
• Source: Celltex Therapeutics Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

This is a single patient emergency expanded access clinical study to assess the safety of administering autologous AdMSCs to an incurable Alzheimer disease patient. The study subject will be evaluated for disease-associated severity according to symptoms, cognitive function, memory, and quality of life.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• The patient is diagnosed with later stage of Alzheimer Disease with sever cognitive disability.

• All current anti-Alzheimer medicines cannot prevent disease progression and the patient's mental and physical ability persistently declined

• Patient's legal guardian and caregiver must voluntarily sign an approved written consent form after ample explanation of the proposed therapy.

Exclusion Criteria:

• Current diagnosis of malignancy

• Renal/liver dysfunction: Exceed two times as normal subject

• Pregnant or nursing

• Received other trial drugs within 30 days after participation of this study

• Experienced major surgery or trauma in the last 14 days

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• Adipose-Derived Mesenchymal Stem Cells

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Celltex Therapeutics Corporation